Business Description
Sino Biopharmaceutical Ltd
ISIN : KYG8167W1380
Share Class Description:
SBMFF: Ordinary SharesTotal Employee Number:
21,435Compare
Compare
Traded in other countries / regions
01177.Hong KongSINOBIO19.ThailandSMZ1.GermanySBMFF.USA IPO Date
2010-02-12Description
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.43 | |||||
Equity-to-Asset | 0.4 | |||||
Debt-to-Equity | 0.52 | |||||
Debt-to-EBITDA | 2.25 | |||||
Interest Coverage | 24.78 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.84 | |||||
Beneish M-Score | -2.87 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.4 | |||||
3-Year EBITDA Growth Rate | 9.5 | |||||
3-Year EPS without NRI Growth Rate | 19 | |||||
3-Year FCF Growth Rate | 20.1 | |||||
3-Year Book Growth Rate | 1.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 3.97 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.1 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 75.25 | |||||
9-Day RSI | 66.58 | |||||
14-Day RSI | 56.32 | |||||
3-1 Month Momentum % | -16.53 | |||||
6-1 Month Momentum % | -28.95 | |||||
12-1 Month Momentum % | -11.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.37 | |||||
Quick Ratio | 1.28 | |||||
Cash Ratio | 0.91 | |||||
Days Inventory | 142.18 | |||||
Days Sales Outstanding | 68.95 | |||||
Days Payable | 122.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.01 | |||||
Dividend Payout Ratio | 0.38 | |||||
3-Year Dividend Growth Rate | -2.1 | |||||
Forward Dividend Yield % | 2 | |||||
5-Year Yield-on-Cost % | 3.28 | |||||
3-Year Average Share Buyback Ratio | 1.1 | |||||
Shareholder Yield % | -3.37 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.07 | |||||
Operating Margin % | 21.69 | |||||
Net Margin % | 7.29 | |||||
EBITDA Margin % | 22.62 | |||||
FCF Margin % | 23.92 | |||||
OCF Margin % | 29.31 | |||||
ROE % | 7.32 | |||||
ROA % | 3.25 | |||||
ROIC % | 9.61 | |||||
3-Year ROIIC % | 9.04 | |||||
ROC (Joel Greenblatt) % | 71.28 | |||||
ROCE % | 14.85 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 37.3 | |||||
Forward PE Ratio | 18.74 | |||||
PE Ratio without NRI | 23.59 | |||||
Shiller PE Ratio | 18.15 | |||||
Price-to-Owner-Earnings | 16.91 | |||||
PS Ratio | 2.72 | |||||
PB Ratio | 2.78 | |||||
Price-to-Tangible-Book | 3.54 | |||||
Price-to-Free-Cash-Flow | 11.39 | |||||
Price-to-Operating-Cash-Flow | 9.29 | |||||
EV-to-EBIT | 12.08 | |||||
EV-to-Forward-EBIT | 17.23 | |||||
EV-to-EBITDA | 12.08 | |||||
EV-to-Forward-EBITDA | 12.04 | |||||
EV-to-Revenue | 2.73 | |||||
EV-to-Forward-Revenue | 3.37 | |||||
EV-to-FCF | 11.44 | |||||
Price-to-GF-Value | 1.1 | |||||
Price-to-Projected-FCF | 1.25 | |||||
Price-to-Median-PS-Value | 0.79 | |||||
Price-to-Graham-Number | 1.93 | |||||
Earnings Yield (Greenblatt) % | 8.28 | |||||
FCF Yield % | 8.93 | |||||
Forward Rate of Return (Yacktman) % | -1.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SBMFF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sino Biopharmaceutical Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4,472.211 | ||
| EPS (TTM) ($) | 0.018 | ||
| Beta | 1.2592 | ||
| 3-Year Sharpe Ratio | 0.43 | ||
| 3-Year Sortino Ratio | 0.8 | ||
| Volatility % | 51.02 | ||
| 14-Day RSI | 56.32 | ||
| 14-Day ATR ($) | 0.004693 | ||
| 20-Day SMA ($) | 0.615249 | ||
| 12-1 Month Momentum % | -11.04 | ||
| 52-Week Range ($) | 0.5928 - 1.24 | ||
| Shares Outstanding (Mil) | 17,773.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sino Biopharmaceutical Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sino Biopharmaceutical Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-18 | In 34 days | ||
| HKD 0.050000 Cash Dividend | 2026-06-24 | 0.60 (+0.00%) | ||
| General meeting for 2025 | 2026-06-17 11:00 | 0.63 (+0.00%) | ||
| Annual report for 2025 | 2026-04-29 | 0.76 (+0.00%) | ||
| HKD 0.050000 Cash Dividend | 2025-08-29 | 0.99 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-18 | 0.99 (+0.00%) | ||
| HKD 0.040000 Cash Dividend | 2025-06-16 | 0.70 (+0.00%) | ||
| General meeting for 2024 | 2025-06-10 15:00 | 0.55 (+0.00%) | ||
| Annual report for 2024 | 2025-04-29 | 0.49 (+0.00%) | ||
| HKD 0.030000 Cash Dividend | 2024-09-10 | 0.38 (+0.00%) |
Show
Entries
Sino Biopharmaceutical Ltd Frequently Asked Questions
What is Sino Biopharmaceutical Ltd(SBMFF)'s stock price today?
The current price of SBMFF is $0.64. The 52 week high of SBMFF is $1.24 and 52 week low is $0.59.
When is next earnings date of Sino Biopharmaceutical Ltd(SBMFF)?
The next earnings date of Sino Biopharmaceutical Ltd(SBMFF) is 2026-08-18 Est..
Does Sino Biopharmaceutical Ltd(SBMFF) pay dividends? If so, how much?
The Dividend Yield %  of Sino Biopharmaceutical Ltd(SBMFF) is 2.01% (As of Today), Highest Dividend Payout Ratio of Sino Biopharmaceutical Ltd(SBMFF) was 0.75. The lowest was 0.05. And the median was 0.27. The  Forward Dividend Yield % of Sino Biopharmaceutical Ltd(SBMFF) is 2%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on OTCPK:SBMFF
No articles.
Press Release
Articles on Sino Biopharmaceutical Ltd
No articles.
Headlines
See More- 1
Jul 08, 2026
Sino Biopharma receives Chinese rights to two GSK respiratory drugs
Seeking Alpha • 9:26am
AstraZeneca to pay $200M upfront for Sino Biopharmaceutical’s COPD drug license deal
Seeking Alpha • 11:38pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers